Back20/20 Biolabs Common Stock Overview

20/20 Biolabs Common Stock Total Current Liabilities

Latest total current liabilities for AIDX: $2.6M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$2.55M

Peer trimmed avg / median

Loading

20/20 Biolabs Common Stock Total Current Liabilities History

Loading

20/20 Biolabs Common Stock vs. peers: Total Current Liabilities Comparison

Loading

20/20 Biolabs Common Stock Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

20/20 Biolabs Common Stock (AIDX) FAQ

20/20 Biolabs Common Stock (AIDX) currently reports a total current liabilities of $2.6M as of June 2026. Use the charts on this page to explore 20/20 Biolabs Common Stock's total current liabilities history and peer comparisons.

20/20 Biolabs Common Stock reported $2.6M in total current liabilities as of June 2026. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $2.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for 20/20 Biolabs Common Stock, and consider following AIDX for alerts when major investors trade the stock.